Business Description
Alumis Inc
NAICS : 541714
SIC : 2834
ISIN : US0223071020
Total Employee Number:
239Description
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.79 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.71 | |||||
Beneish M-Score | -3.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -21.4 | |||||
3-Year EPS without NRI Growth Rate | -19.7 | |||||
3-Year FCF Growth Rate | -14.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.78 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 100.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.36 | |||||
9-Day RSI | 19.77 | |||||
14-Day RSI | 23.24 | |||||
3-1 Month Momentum % | 33.01 | |||||
6-1 Month Momentum % | -6.06 | |||||
12-1 Month Momentum % | 489.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.74 | |||||
Quick Ratio | 6.74 | |||||
Cash Ratio | 6.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.4 | |||||
Shareholder Yield % | -22.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5639.05 | |||||
Net Margin % | -5933.46 | |||||
EBITDA Margin % | -5591.36 | |||||
FCF Margin % | -4755.33 | |||||
OCF Margin % | -4749.91 | |||||
ROE % | -100.19 | |||||
ROA % | -80.01 | |||||
ROIC % | -408.17 | |||||
3-Year ROIIC % | -348.36 | |||||
ROC (Joel Greenblatt) % | -1172.61 | |||||
ROCE % | -87.95 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 170.62 | |||||
PB Ratio | 3.15 | |||||
Price-to-Tangible-Book | 3.21 | |||||
EV-to-EBIT | -2.43 | |||||
EV-to-EBITDA | -2.45 | |||||
EV-to-Revenue | 137.14 | |||||
EV-to-Forward-Revenue | 72.71 | |||||
EV-to-FCF | -2.88 | |||||
| Price-to-Net-Current-Asset-Value | 3.51 | |||||
| Price-to-Net-Cash | 3.62 | |||||
Earnings Yield (Greenblatt) % | -41.15 | |||||
FCF Yield % | -23.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alumis Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.398 | ||
| EPS (TTM) ($) | -3.85 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 167.31 | ||
| 14-Day RSI | 23.24 | ||
| 14-Day ATR ($) | 2.147936 | ||
| 20-Day SMA ($) | 21.4925 | ||
| 12-1 Month Momentum % | 489.57 | ||
| 52-Week Range ($) | 3.76 - 31.35 | ||
| Shares Outstanding (Mil) | 129.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alumis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alumis Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 67 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 25.55 (+0.16%) | ||
| General meeting for 2026 | 2026-06-30 09:00 | 27.14 (+2.80%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 24.86 (+6.15%) | ||
| the Phase 3 ONWARD data being presented at AAD | 2026-03-29 19:00 | 24.80 (-4.65%) | ||
| Annual report for 2025 | 2026-03-19 | 25.42 (-3.46%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 25.42 (-3.46%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-09 10:40 | 26.90 (-0.33%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 15:20 | 29.39 (+1.82%) | ||
| Guidance call for 2026 | 2026-02-12 09:00 | 25.63 (-3.47%) |
Show
Entries
Alumis Inc Frequently Asked Questions
What is Alumis Inc(ALMS)'s stock price today?
The current price of ALMS is $11.09. The 52 week high of ALMS is $31.35 and 52 week low is $3.76.
When is next earnings date of Alumis Inc(ALMS)?
The next earnings date of Alumis Inc(ALMS) is 2026-11-13 Est..
Does Alumis Inc(ALMS) pay dividends? If so, how much?
Alumis Inc(ALMS) does not pay dividend.
Press Release
Articles on Alumis Inc
Alumis (ALMS) LUMUS Trial Misses Primary Endpoints; Market Pricing Reflects Growth Expectations
6 days ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers